Resources | NITAG RESOURCE CENTER

2024 ∙ ATAGI

ATAGI statement on Nirsevimab for the prevention of severe disease due to respiratory syncytial virus (RSV) in infants

2024 ∙ Louise Henaff, Dace Zavadska, Mario Melgar, Johanna Fihman, Christoph Steffen, Joachim Hombach

The role of NITAGs in government decisions on vaccine use: insights from the Fifth Global NITAG Network meeting

2024 ∙ NACI

Guidance on an additional dose of COVID-19 vaccines in the spring for individuals at high risk of severe illness due to COVID-19

2024

Meningococcal vaccines: WHO position paper on the use of multivalent meningococcal conjugate vaccines in countries of the African meningitis belt, January 2024

2023 ∙ JCVI

JCVI statement on a childhood varicella (chickenpox) vaccination programme

2023 ∙ JCVI

JCVI statement on the COVID-19 vaccination programme for autumn 2023 - updated on October 2023

2023

Off-label vaccine use: explanatory note for countries

2023

NITAG Maturity Assessment Tool (NMAT)

2023

Supporting the routine use of evidence during the policy-making process: a WHO checklist

2023 ∙ NIAC

NIAC RECOMMENDATIONS FOR PASSIVE IMMUNISATION AND VACCINATION AGAINST RESPIRATORY SYNCYTIAL VIRUS IN INFANTS, CHILDREN AND OLDER ADULTS